Search results for " papillomavirus"

showing 10 items of 108 documents

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 y…

2009

This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines, Cervarix (GlaxoSmithKline) and Gardasil (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n = 1106) were stratified by age (18-26, 27-35, 36-45 years) and randomized (1:1) to receive Cervarix (Months 0, 1, 6) or Gardasil (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum neutralizing antibodies, as measured by pseudovirion-based neutralization assay (PBNA…

Adultmedicine.medical_specialtyAdolescentImmunologyAntibodies ViralCancer VaccinesSerologyYoung AdultHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Neutralization TestsInternal medicinemedicineHumansPapillomavirus VaccinesGeneral Pharmacology Toxicology and PharmaceuticsNeutralizing antibodyPapillomaviridaeCervical cancerbiologybusiness.industryImmunogenicityGardasilPapillomavirus InfectionsMiddle Agedmedicine.diseaseAntibodies NeutralizingVaccinationImmunologyCohortbiology.proteinFemaleCervarixbusinessmedicine.drugHuman Vaccines
researchProduct

Post-reproductive aged women: a lost generation in the cervical cancer screening programme

2020

The aims of the study were to find out why some post-reproductive aged women did not participate in the organised cervical cancer screening programme in Latvia and to clarify factors that would motivate them to take part. A cross-sectional study was carried out between January and July 2017 among female patients in three general practitioner (GP) practices. GP practice nurses used the Latvian national health service database to identify women aged 25–70 who had not participated in the organised programme for the last 3 years. Participants were asked to complete a specially developed questionnaire. The results were then compared between three age groups: 25–34, 35–49 and 50–70 years. Include…

Adultmedicine.medical_specialtyUterine Cervical NeoplasmsCervical cancer screeningState Medicine03 medical and health sciences0302 clinical medicineGeneral PractitionersMedicineHumansMass ScreeningPharmacology (medical)030212 general & internal medicineHuman papillomavirusEarly Detection of CancerAged030219 obstetrics & reproductive medicinebusiness.industryObstetricsObstetrics and GynecologyMiddle AgedPatient Acceptance of Health CareLatviaCross-Sectional StudiesReproductive MedicineFemalebusiness
researchProduct

TP53 codon 72 polymorphism and cervical cancer

2009

Background Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer.Methods Individual data on 7946 cases and 7888 controls from 49 different st…

ArginineMESH : Polymorphism GeneticMESH: Genes p53MESH : AgedPhysiologyUterine Cervical NeoplasmsMESH: Papillomavirus Infections[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineGenotypeMESH : FemaleCervical cancerGeneticsMESH: AgedMESH : Papillomavirus Infections0303 health sciencesMESH: Middle AgedHPV infectionMESH: Genetic Predisposition to DiseaseMiddle AgedMESH : AdultWILD-TYPE P53Hardy–Weinberg principle3. Good healthMESH: Uterine Cervical NeoplasmsOncologyMESH: Young Adult030220 oncology & carcinogenesisMeta-analysisFemaleAdultAdolescentMESH : Uterine Cervical NeoplasmsMESH : Young Adult[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Genes p5303 medical and health sciencesYoung AdultSQUAMOUS INTRAEPITHELIAL LESIONSMESH : AdolescentINDIAN WOMENMESH: Polymorphism GeneticmedicineHumansGenetic Predisposition to DiseaseMESH : Middle AgedAllele030304 developmental biologyAgedMESH: AdolescentMESH: HumansPolymorphism GeneticHUMAN-PAPILLOMAVIRUS TYPE-16business.industryP53 ARG72PRO POLYMORPHISMHEALTHY WOMENPapillomavirus InfectionsMESH : HumansMESH: AdultOdds ratiomedicine.diseaseGenes p53GENOTYPESHARDY-WEINBERG EQUILIBRIUMRISK-FACTORSMESH : Genetic Predisposition to DiseasebusinessMESH: FemaleHPV INFECTIONLancet Oncology
researchProduct

Detection of bovine Papillomavirus and efficacy of treatment using saponinDetection of bovine Papillomavirus and efficacy of treatment using saponin

2014

Papillomas of teats and udders in cows may cause skin lesions, thelitis, mastitis and poor milking resulting in economic losses. We describe an outbreak of bovine papillomavirus (BPV) and successful treatment with a purified extract of Quillaja saponaria bark (Quil-A).

Bovine papillomavirus saponin treatment
researchProduct

A quest for initiating cells of head and neck cancer and their treatment.

2010

The biology of head and neck squamous cell carcinomas (HNSCC) and other cancers have been related to cancer stem-like cells (CSC). Specific markers, which vary considerably depending on tumor type or tissue of origin, characterize CSC. CSC are cancer initiating, sustaining and mostly quiescent. Compared to bulk tumors, CSC are less sensitive to chemo- and radiotherapy and may have low immunogenicity. Therapeutic targeting of CSC may improve clinical outcome. HNSCC has two main etiologies: human papillomavirus, a virus infecting epithelial stem cells, and tobacco and alcohol abuse. Here, current knowledge of HNSCC-CSC biology is reviewed and parallels to CSC of other origin are drawn where n…

Cancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentepithelial mesenchymal transitionSox2Reviewlcsh:RC254-282NanogMetastasisstemnessSOX2RadioresistancemedicinemetastasisEpithelial–mesenchymal transitionALDH1human papillomavirusbusiness.industryHead and neck cancerCancerchemoresistancelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOct3/4Radiation therapyradioresistancestomatognathic diseasesOncologyCancer researchimmunotherapyStem cellbusinessCancers
researchProduct

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

2013

Human papillomavirus (HPV) 58 accounts for a notable proportion of cervical cancers in East Asia and parts of Latin America, but it is uncommon elsewhere. The reason for such ethnogeographical predilection is unknown. In our study, nucleotide sequences of E6 and E7 genes of 401 HPV58 isolates collected from 15 countries/cities across four continents were examined. Phylogenetic relationship, geographical distribution and risk association of nucleotide sequence variations were analyzed. We found that the E6 genes of HPV58 variants were more conserved than E7. Thus, E6 is a more appropriate target for type-specific detection, whereas E7 is more appropriate for strain differentiation. The frequ…

Cancer ResearchSettore MED/07 - Microbiologia E Microbiologia Clinicacervical cancerSettore MED/06 - Oncologia MedicaPapillomavirus E7 ProteinsUterine Cervical NeoplasmsCervix UteriphylogenyPolymerase Chain ReactionViralPapillomaviridaePapillomaviridaePhylogenyCancerOncogene ProteinsCervical cancerGeneticsTumorGeographybiologyNucleic acid sequenceDNA NeoplasmPrognosisInfectious DiseasesOncologyHIV/AIDSFemaleHPVhuman papillomavirus type 58 E6 and E7 sequence variationsOncology and CarcinogenesisCervical intraepithelial neoplasiaRisk AssessmentArticleVaccine Relatedoncogenic riskClinical ResearchPhylogeneticsGenetic variationGeneticsBiomarkers TumormedicineHumansOncology & CarcinogenesisGenePreventionPapillomavirus InfectionsGenetic VariationInternational AgenciesDNAOncogene Proteins ViralOdds ratioUterine Cervical Dysplasiamedicine.diseasebiology.organism_classificationVirologyvariantNeoplasmSexually Transmitted InfectionsCapsid ProteinsBiomarkersFollow-Up Studies
researchProduct

Comprehensive Analysis of VEGFR2 Expression in HPV-Positive and -Negative OPSCC Reveals Differing VEGFR2 Expression Patterns

2021

VEGF signaling regulated by the vascular endothelial growth factor receptor 2 (VEGFR2) plays a decisive role in tumor angiogenesis, initiation and progression in several tumors including HNSCC. However, the impact of HPV-status on the expression of VEGFR2 in OPSCC has not yet been investigated, although HPV oncoproteins E6 and E7 induce VEGF-expression. In a series of 56 OPSCC with known HPV-status, VEGFR2 expression patterns were analyzed both in blood vessels from tumor-free and tumor-containing regions and within tumor cells by immunohistochemistry using densitometry. Differences in subcellular colocalization of VEGFR2 with endothelial, tumor and stem cell markers were determined by doub…

Cancer Researchcancer stem cellAngiogenesisNeoplasms. Tumors. Oncology. Including cancer and carcinogensKinase insert domain receptorBiologyrespiratory systemStem cell markerArticlemedicine.anatomical_structureOncologyCancer stem cellvascular endothelial growth factor receptor 2Cancer cellCancer researchmedicinecardiovascular systemoropharyngeal squamous cell carcinomaImmunohistochemistryAutocrine signallinghuman papillomavirusRC254-282Blood vesselcirculatory and respiratory physiology
researchProduct

Author response: ADAM17-dependent signaling is required for oncogenic human papillomavirus entry platform assembly

2019

Cancer researchHuman papillomavirusBiology
researchProduct

Infezione orale da Human papillomavirus: dalla verruca al carcinoma orale. Epidemiologia, clinica, prevenzione e terapia

2015

Riasunto Obiettivi Prendere in esame l’epidemiologia e le manifestazioni cliniche dell’infezione orale da Human papillomavirus (HPV), con particolare attenzione alle lesioni con potenziale oncologico maligno. Materiali e metodi E stata condotta una revisione sistematica della letteratura finalizzata a descrivere lo stato dell’arte in merito all’infezione da HPV nella mucosa orofaringea e alle relative modalita di trasmissione del virus con particolare riferimento alla possibile contemporanea infezione in sedi anatomiche multiple. Vengono approfonditi gli aspetti riguardanti la prevenzione e il controllo dell’infezione mediante la somministrazione di vaccini e lo svolgimento di campagne cono…

Carcinoma of the oropharynxHuman papillomavirubusiness.industryMedicineOrthodonticsHpv testOral SurgeryHuman papillomavirusbusinessHumanitiesSexually transmitted oral infectionHPV vaccineHPV test
researchProduct

976Screening for cervical cancer with Human Papillomavirus testing: stand-alone is preferable over co-testing with cytology

2021

Abstract Background Cervical cancer screening can be conducted with cytology and Human Papillomavirus (HPV) testing but few studies have compared the latter directly to concomitant testing (co-testing). We compared these strategies to determine appropriate screening. Methods Within a randomised population-based cohort study conducted around Mainz, Germany, eligible women (≥30 years) were screened via Pap smear, liquid-based cytology (LBC) and HPV testing (HC2) and HPV genotyped post hoc (PCR). These tests formed three strategies: cytology (Pap or LBC) and HPV (HC2 or PCR) stand-alone and co-testing. Screen positives and 5% negative women were invited to colposcopy. Absolute and relative sen…

Cervical cancerOncologyColposcopymedicine.medical_specialtyRandomizationmedicine.diagnostic_testEpidemiologybusiness.industryGeneral Medicinemedicine.diseaseCervical cancer screeningInternal medicineCytologyMedicineHuman papillomavirusbusinessInternational Journal of Epidemiology
researchProduct